BioTiChe today announced its formation as a biotechnology company focused on the discovery and development of innovative small-molecule therapeutics.
Built on the principle “From Target to Clinical Candidate, Together,” BioTiChe operates as an integrated chemistry and biology discovery company creating small molecules for central nervous system (CNS) and lysosomal diseases.
BioTiChe was established as a spin-out from Autifony Therapeutics building on the scientific expertise and experience of its founding team. The company brings together a multidisciplinary team of chemists and biologists with a strong track record in ion channel research and drug discovery.
The creation of BioTiChe represents a strategic step to establish an independent, dedicated environment for advancing innovative small molecules toward clinical development.
Dr. Giuseppe Alvaro, Chief Executive Officer and co-founder of BioTiChe, commented:
BioTiChe represents an exciting and meaningful opportunity for both my team and me. After many years working within pharmaceutical companies, we now have the chance to fully leverage our extensive experience in drug discovery in a more agile and focused environment. Our goal is to apply this expertise to efficiently and rapidly identify new candidate molecules within innovative and high-impact projects.
I am especially looking forward to collaborating with partners who share a strong alignment with our scientific vision and operate at the forefront of research. Building these synergistic relationships will be key to driving innovation and achieving meaningful results together.
“BioTiChe represents an exciting and meaningful opportunity… We now have the chance to fully leverage out extensive experience in drug discovery in a more agile and focused environment”
– DR. GIUSEPPE ALVARO
Dr. Nadia Pilati, Co-Founder & Vice President, Biology & External Operations,commented:
“BioTiChe is the realization of a vision we have pursued for many years, built on our profound passion for science and numbers. It reflects the dedication of a team working together with aligned goals. This is not an achievement in itself, it is just the beginning. The real accomplishment, will come from discovering and developing molecules that one day could become medicines for patients.” Dr. Agostino Marasco, Co-Founder & Vice President, Chemistry & Internal Operations commented:
“BioTiChe was born from the collective experience of professionals who have spent years navigating the realities of pharma and biotech innovation. This journey gave us a clear understanding of what it truly takes to move a discovery project forward. By integrating chemistry, biology, and hands-on project leadership into a single operational model, BioTiChe represents the kind of focused, agile partner today’s biotech innovators are looking for. BioTiChe is headquartered in Padua and operates with an integrated approach combining medicinal chemistry and biology to drive drug discovery programs forward”.
The company is built on the continuity of a highly experienced scientific team, whose expertise forms the foundation of BioTiChe’s research and development strategy.
